Please use this identifier to cite or link to this item: https://apo.ansto.gov.au/dspace/handle/10238/5239
Title: In vivo analysis of serotonin clearance in rat hippocampus reveals that repeated administration of p-methoxyamphetamine (PMA), but not 3,4-methylenedioxymethamphetamine (MDMA), leads to long-lasting deficits in serotonin transporter function
Authors: Callaghan, PD
Owens, WA
Javors, MA
Sanchez, TA
Jones, DJ
Irvine, RJ
Daws, LC
Keywords: Neuroregulators
Serotonin
Brain
Analeptics
Psychotropic drugs
Hallucinogens
Issue Date: 20-Dec-2006
Publisher: Wiley
Citation: Callaghan, P. D., Owens, W. A., Javors, M. A., Sanchez, T. A., Jones, D. J., Irvine, R. J., & Daws, L. C. (2007). In vivo analysis of serotonin clearance in rat hippocampus reveals that repeated administration of pmethoxyamphetamine (PMA), but not 3,4-methylenedioxymethamphetamine (MDMA), leads to long-lasting deficits in serotonin transporter function. Journal of Neurochemistry, 100(3), 617-627. doi:10.1111/j.1471-4159.2006.04247.x
Abstract: p-Methoxyamphetamine (PMA) has been implicated in fatalities as a result of ‘ecstasy’ (MDMA) overdose worldwide. Like MDMA, acute effects are associated with marked changes in serotonergic neurotransmission, but the long-term effects of PMA are poorly understood. The aim of this study was to determine the effect of repeated PMA administration on in vitro measures of neurodegeneration: serotonin (5-HT) uptake, 5-HT transporter (SERT) density and 5-HT content in the hippocampus, and compare with effects on in vivo 5-HT clearance. Male rats received PMA, MDMA (4 or 15 mg/kg s.c., twice daily) or vehicle for 4 days and 2 weeks later indices of SERT function were measured. [3H]5-HT uptake into synaptosomes and [3H]cyanoimipramine binding to the SERT were significantly reduced by both PMA and MDMA treatments. 5-HT content was reduced in MDMA-, but not PMA-treatment. In contrast, clearance of locally applied 5-HT measured in vivo by chronoamperometry was only reduced in rats treated with 15 mg/kg PMA. The finding that 5-HT clearance in vivo was unaltered by MDMA treatment suggests that in vitro measures of 5-HT axonal degeneration do not necessarily predict potential compensatory mechanisms that maintain SERT function under basal conditions. © 1999-2020 John Wiley & Sons, Inc.
Gov't Doc #: 4531
URI: http://dx.doi.org/10.1111/j.1471-4159.2006.04247.x
http://apo.ansto.gov.au/dspace/handle/10238/5239
ISSN: 1471-4159
Appears in Collections:Journal Articles

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.